<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="364735">
  <stage>Registered</stage>
  <submitdate>7/08/2013</submitdate>
  <approvaldate>9/08/2013</approvaldate>
  <actrnumber>ACTRN12613000892718</actrnumber>
  <trial_identification>
    <studytitle>A Randomised, Placebo-Controlled, Double-Blind, Single Dose Escalation Study to evaluate the Safety, Tolerability and Pharmacokinetics of Betahistine Dihydrochloride Following a Single Intranasal Dose in Healthy Male and Female Volunteers.</studytitle>
    <scientifictitle>A Randomised, Placebo-Controlled, Double-Blind, Single Dose Escalation Study to evaluate the Safety, Tolerability and Pharmacokinetics of Betahistine Dihydrochloride Following a Single Intranasal Dose in Healthy Male and Female Volunteers.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>OME (Otitis Media with Effusion)</healthcondition>
    <conditioncode>
      <conditioncode1>Ear</conditioncode1>
      <conditioncode2>Other ear disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Single ascending dose of a betahistine dihydrochloride or placebo administered intranasally in healthy male and female volunteers.  The dose levels planned for this study are 10, 20 and 40 mg in 3 cohorts.  8 participants in each cohort will be dosed with either the test medication or placebo in a double-blind manner.  The duration of each cohort is 7 days post dose.</interventions>
    <comparator>The vehicle will be used as the matched placebo formulation.  Both the test drug and placebo are administered intranasally.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Safety and tolerability of a single intranasal dose of betahistine dihydrochloride (BH) of 10, 20 or 40 mg in healthy male and female volunteers will be assessed on the basis of adverse events reported, blood pressure, heart rate, body temperature (oral), electrocardiograms (ECGs), clinical laboratory  tests, physical examination  and  tympanometry.  The methods used will be medical equipment and questioning.   No specific adverse events are expected.</outcome>
      <timepoint>Subjects will be continuously  monitored for adverse events, blood pressure, heart rate, body temperature, electrocardiograms (ECGs), clinical laboratory tests, physical examination  and tympanometry  whist on study (from predose to Day 7).</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>To characterise the single dose pharmacokinetics of betahistine dihydrochloride at 10mg, 20mg, 40mg in healthy male and female volunteers.

Plasma samples derived from venous blood will be analysed using a validated liquid chromatographic (LC) tandem mass spectrometric detection (MS/MS) achiral method to determine the concentrations of betahistine dihydrochloride and its major metabolite, 2-pyridylacetic acid, at a range of timepoints.  This information will then be used to determine single dose pharmacokinetic parameters including Cmax, Tmax, AUC and T(half).</outcome>
      <timepoint>The pharmacokinetics of betahistine dihydrochloride will be collected at predetermined timepoints through the study and measured after each cohort.  These time points are: predose, 2, 5, 10, 15, 20, 30, 60, 90 minutes and 2, 6, and 12 hours, 24 hours postdose, Day 4 and Day 7.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To explore the pharmacodynamic effect of BH on Eustachian tube function using tympanometry testing.</outcome>
      <timepoint>Predose, then at 10 minutes, 2 hours and 6 hours, 24 hours postdose.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Healthy male and female volunteers having Body Mass Index (MBI) between 18 and 30kg/m2 inclusive.
Normal (Type A) tympanometric  measurements  at screening consistent with the normal healthy adult population.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>45</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>History or presence of clinically relevant cardiovascular, pulmonary, gastrointestinal, hepatic, renal, metabolic,  haematological, neurologic, psychiatric,  systemic, ocular, or infectious disease; any acute infectious disease or signs of acute illness, especially of the ear, nose or throat (ENT).
History of recurrent ENT infections, irritation or localized reaction to intranasally applied agents.
Recent ENT surgery (within 3 months of screening).</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate>12/08/2013</anticipatedstartdate>
    <actualstartdate>25/08/2013</actualstartdate>
    <anticipatedenddate />
    <actualenddate>25/03/2014</actualenddate>
    <samplesize>24</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>WA,VIC</recruitmentstate>
    <hospital>The Alfred - Prahran </hospital>
    <hospital>Sir Charles Gairdner Hospital - Nedlands</hospital>
    <postcode>3004 - Melbourne</postcode>
    <postcode>6009 - Broadway Nedlands</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Otifex Therapeutics Pty Ltd</primarysponsorname>
    <primarysponsoraddress>Level 9, 278 Collins Street,
Melbourne VIC 3000</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Otifex Therapeutics Pty Ltd</fundingname>
      <fundingaddress>Level 9, 278 Collins Street,
Melbourne VIC 3000</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Betahistine dihydrochloride administered off-label intranasally is an experimental drug being investigated  for its potential as a treatment for otitis media with effusion for this clinical trial.  lt is hoped that this information will lead to improved clinical management of this condition.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Alfred Hospital Ethics Committee</ethicname>
      <ethicaddress>The Alfred Hospital
55 Commercial Rd  Melbourne VIC 3004</ethicaddress>
      <ethicapprovaldate>1/08/2013</ethicapprovaldate>
      <hrec>259/13</hrec>
      <ethicsubmitdate>17/07/2013</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Bellberry Limited</ethicname>
      <ethicaddress>129 Glen Osmond Rd 
Eastwood SA 5063</ethicaddress>
      <ethicapprovaldate>18/12/2013</ethicapprovaldate>
      <hrec>2013-11-625</hrec>
      <ethicsubmitdate>20/11/2013</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Janakan Krishnarajah</name>
      <address>Medical Director &amp; CEO
Linear Clinical Research Ltd
QEII Medical Centre, 1st Floor, B Block, Hospital Avenue
Nedlands WA 6009</address>
      <phone>+61 8 6382 5100</phone>
      <fax>+61 8 9381 4453</fax>
      <email>jkrishnarajah@linear.org.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Janakan Krishnarajah</name>
      <address>Medical Director &amp; CEO
Linear Clinical Research Ltd
QEII Medical Centre, 1st Floor, B Block, Hospital Avenue
Nedlands WA 6009</address>
      <phone>+61 8 6382 5100</phone>
      <fax>+61 8 9381 4453</fax>
      <email>jkrishnarajah@linear.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Christopher Wraight</name>
      <address>Otifex Therapeutics Pty Ltd
Level 9, 278 Collins Street
Melbourne VIC 3000</address>
      <phone>+61 3 9657 0700</phone>
      <fax />
      <email>cwraight@otifex.com</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Christopher Wraight</name>
      <address>Otifex Therapeutics Pty Ltd
Level 9, 278 Collins Street
Melbourne VIC 3000</address>
      <phone>+61 3 9657 0700</phone>
      <fax />
      <email>cwraight@otifex.com</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>